(ELAN) Elanco Animal Health - Ratings and Ratios
Parasiticides, Vaccines, Therapeutics, Antibiotics, Feed Additives
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 46.1% |
| Value at Risk 5%th | 60.8% |
| Relative Tail Risk | -19.81% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.32 |
| Alpha | 57.67 |
| CAGR/Max DD | 0.36 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.535 |
| Beta | 1.270 |
| Beta Downside | 1.233 |
| Drawdowns 3y | |
|---|---|
| Max DD | 56.10% |
| Mean DD | 20.68% |
| Median DD | 21.31% |
Description: ELAN Elanco Animal Health November 03, 2025
Elanco Animal Health (NYSE: ELAN) develops, manufactures and markets a broad portfolio of veterinary products for companion animals and livestock. Its pet-care line includes parasiticides, vaccines and therapeutics sold under brands such as Seresto, Advantix, Credelio, Galliprant and Atopica, while its farm-animal segment offers medicated feed additives, injectable antibiotics, vaccines and insecticides for cattle, swine and poultry (e.g., Rumensin, Baytril, Maxiban, AviPro). Distribution is a mix of third-party wholesalers, independent retailers and direct sales to veterinarians and producers.
Key metrics that shape Elanco’s outlook include FY 2023 revenue of roughly $3.2 billion, with the pet-health segment contributing about 55 % and delivering a 12 % YoY growth rate driven by rising pet ownership and premiumization trends in the United States and Europe. The livestock business is sensitive to global protein demand; a 5 % annual increase in meat consumption in emerging markets is a primary growth driver, while feed-cost inflation and regulatory scrutiny on antibiotic use pose margin pressures. Elanco’s R&D pipeline, highlighted by next-generation parasiticides and a pipeline of novel biologics for dairy cattle, is expected to sustain product-launch momentum over the next 12-24 months.
For a deeper, data-driven valuation of ELAN, you may find ValueRay’s analyst toolkit useful for quantifying these drivers and testing scenario outcomes.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (36.0m TTM) > 0 and > 6% of Revenue (6% = 275.5m TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA -0.19pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 44.39% (prev 45.91%; Δ -1.52pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.05 (>3.0%) and CFO 629.0m > Net Income 36.0m (YES >=105%, WARN >=100%) |
| Net Debt (3.52b) to EBITDA (891.0m) ratio: 3.95 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.40 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (496.8m) change vs 12m ago -0.18% (target <= -2.0% for YES) |
| Gross Margin 46.37% (prev 42.68%; Δ 3.69pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 34.22% (prev 33.53%; Δ 0.69pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 0.93 (EBITDA TTM 891.0m / Interest Expense TTM 237.0m) >= 6 (WARN >= 3) |
Altman Z'' 0.31
| (A) 0.15 = (Total Current Assets 3.49b - Total Current Liabilities 1.46b) / Total Assets 13.55b |
| (B) -0.14 = Retained Earnings (Balance) -1.91b / Total Assets 13.55b |
| (C) 0.02 = EBIT TTM 221.0m / Avg Total Assets 13.42b |
| (D) -0.31 = Book Value of Equity -2.10b / Total Liabilities 6.80b |
| Total Rating: 0.31 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 42.89
| 1. Piotroski 3.50pt |
| 2. FCF Yield 2.45% |
| 3. FCF Margin 7.88% |
| 4. Debt/Equity 0.60 |
| 5. Debt/Ebitda 3.95 |
| 6. ROIC - WACC (= -6.70)% |
| 7. RoE 0.55% |
| 8. Rev. Trend 8.22% |
| 9. EPS Trend -18.49% |
What is the price of ELAN shares?
Over the past week, the price has changed by -5.89%, over one month by +1.39%, over three months by +18.83% and over the past year by +80.69%.
Is ELAN a buy, sell or hold?
- Strong Buy: 6
- Buy: 1
- Hold: 8
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ELAN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 24.1 | 10% |
| Analysts Target Price | 24.1 | 10% |
| ValueRay Target Price | 24.7 | 13% |
ELAN Fundamental Data Overview December 02, 2025
P/E Trailing = 323.1429
P/E Forward = 22.1729
P/S = 2.4481
P/B = 1.7131
P/EG = 4.0294
Beta = 1.867
Revenue TTM = 4.59b USD
EBIT TTM = 221.0m USD
EBITDA TTM = 891.0m USD
Long Term Debt = 3.96b USD (from longTermDebt, last quarter)
Short Term Debt = 62.0m USD (from shortTermDebt, last quarter)
Debt = 4.02b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.52b USD (from netDebt column, last quarter)
Enterprise Value = 14.76b USD (11.24b + Debt 4.02b - CCE 505.0m)
Interest Coverage Ratio = 0.93 (Ebit TTM 221.0m / Interest Expense TTM 237.0m)
FCF Yield = 2.45% (FCF TTM 362.0m / Enterprise Value 14.76b)
FCF Margin = 7.88% (FCF TTM 362.0m / Revenue TTM 4.59b)
Net Margin = 0.78% (Net Income TTM 36.0m / Revenue TTM 4.59b)
Gross Margin = 46.37% ((Revenue TTM 4.59b - Cost of Revenue TTM 2.46b) / Revenue TTM)
Gross Margin QoQ = 53.39% (prev 46.49%)
Tobins Q-Ratio = 1.09 (Enterprise Value 14.76b / Total Assets 13.55b)
Interest Expense / Debt = 1.29% (Interest Expense 52.0m / Debt 4.02b)
Taxrate = 32.0% (-16.0m / -50.0m)
NOPAT = 150.3m (EBIT 221.0m * (1 - 32.00%))
Current Ratio = 2.40 (Total Current Assets 3.49b / Total Current Liabilities 1.46b)
Debt / Equity = 0.60 (Debt 4.02b / totalStockholderEquity, last quarter 6.75b)
Debt / EBITDA = 3.95 (Net Debt 3.52b / EBITDA 891.0m)
Debt / FCF = 9.72 (Net Debt 3.52b / FCF TTM 362.0m)
Total Stockholder Equity = 6.49b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.27% (Net Income 36.0m / Total Assets 13.55b)
RoE = 0.55% (Net Income TTM 36.0m / Total Stockholder Equity 6.49b)
RoCE = 2.11% (EBIT 221.0m / Capital Employed (Equity 6.49b + L.T.Debt 3.96b))
RoIC = 1.40% (NOPAT 150.3m / Invested Capital 10.73b)
WACC = 8.10% (E(11.24b)/V(15.26b) * Re(10.69%) + D(4.02b)/V(15.26b) * Rd(1.29%) * (1-Tc(0.32)))
Discount Rate = 10.69% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.41%
[DCF Debug] Terminal Value 65.25% ; FCFE base≈369.2m ; Y1≈305.0m ; Y5≈220.9m
Fair Price DCF = 5.49 (DCF Value 2.73b / Shares Outstanding 496.9m; 5y FCF grow -20.95% → 3.0% )
EPS Correlation: -18.49 | EPS CAGR: -2.63% | SUE: 1.48 | # QB: 3
Revenue Correlation: 8.22 | Revenue CAGR: 0.57% | SUE: 2.58 | # QB: 3
EPS next Quarter (2026-03-31): EPS=0.35 | Chg30d=+0.003 | Revisions Net=+0 | Analysts=7
EPS next Year (2026-12-31): EPS=1.03 | Chg30d=+0.026 | Revisions Net=+4 | Growth EPS=+10.3% | Growth Revenue=+5.3%
Additional Sources for ELAN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle